{"id":5035,"date":"2025-07-08T09:51:27","date_gmt":"2025-07-08T09:51:27","guid":{"rendered":"https:\/\/scientificworld.org\/?p=5035"},"modified":"2025-07-08T09:51:32","modified_gmt":"2025-07-08T09:51:32","slug":"diabetes-drug-dapagliflozin-shows-promise-in-treating-liver-disease-study-finds","status":"publish","type":"post","link":"https:\/\/scientificworld.org\/?p=5035","title":{"rendered":"Diabetes Drug Dapagliflozin Shows Promise in Treating Liver Disease, Study Finds"},"content":{"rendered":"\n<p>A clinical trial published in\u00a0<a href=\"http:\/\/dx.doi.org\/10.1136\/bmj-2024-083735\"><em>The BMJ<\/em><\/a>\u00a0reveals that dapagliflozin, a drug commonly used to treat type 2 diabetes, may also benefit patients with metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver\u00a0disease. The study, conducted in China, found that dapagliflozin improved liver inflammation and reduced fibrosis compared to a placebo, offering new hope for patients with this condition.<\/p>\n\n\n\n<p>The trial involved 154 adults diagnosed with MASH, a condition characterized by excess liver fat and inflammation, which can lead to severe scarring (fibrosis) and cirrhosis. Participants were randomly assigned to receive either 10 mg of dapagliflozin or a placebo daily for 48 weeks. The results showed that 53% of those taking dapagliflozin experienced improved MASH symptoms without worsening fibrosis, compared to only 30% in the placebo group. Additionally, 23% of the dapagliflozin group achieved complete resolution of MASH, versus 8% in the placebo group.<\/p>\n\n\n\n<p>Dapagliflozin also demonstrated significant benefits in reducing liver fibrosis, with 45% of participants showing improvement compared to 20% in the placebo group. The drug was well-tolerated, with very few discontinuing treatments due to adverse effects.<\/p>\n\n\n\n<p>While the study\u2019s findings are promising, the researchers noted limitations, including its focus on a predominantly male, Chinese population, which may affect broader applicability. They emphasized the need for larger, long-term trials to confirm these results.<\/p>\n\n\n\n<p>The study authors concluded,&nbsp;<em>\u201cOur findings indicate that dapagliflozin may affect key aspects of MASH by improving both steatohepatitis and fibrosis.\u201d<\/em>&nbsp;In a linked editorial, researchers from Argentina highlighted the growing potential for tailored treatments for MASH, stressing the importance of cardiovascular benefits and accessibility for diverse patient populations.<\/p>\n\n\n\n<p>This study marks a significant step forward in the search for effective treatments for MASH, a condition affecting millions worldwide. As research continues, dapagliflozin could become a valuable tool in managing liver disease, particularly for patients with coexisting diabetes. Future trials will further explore its potential and broader implications.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A clinical trial published in\u00a0The BMJ\u00a0reveals that dapagliflozin, a drug commonly used to treat type 2 diabetes, may also benefit patients with metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver\u00a0disease. The study, conducted in China, found that dapagliflozin improved liver inflammation and reduced fibrosis compared to a placebo, offering new hope for patients with this condition. [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1565],"tags":[2418,1566],"class_list":["post-5035","post","type-post","status-publish","format-standard","hentry","category-health-medicine","tag-diabetes-drug","tag-health-medicine"],"_links":{"self":[{"href":"https:\/\/scientificworld.org\/index.php?rest_route=\/wp\/v2\/posts\/5035","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/scientificworld.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/scientificworld.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/scientificworld.org\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/scientificworld.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5035"}],"version-history":[{"count":2,"href":"https:\/\/scientificworld.org\/index.php?rest_route=\/wp\/v2\/posts\/5035\/revisions"}],"predecessor-version":[{"id":5037,"href":"https:\/\/scientificworld.org\/index.php?rest_route=\/wp\/v2\/posts\/5035\/revisions\/5037"}],"wp:attachment":[{"href":"https:\/\/scientificworld.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/scientificworld.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5035"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/scientificworld.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}